The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
- Authors: Bolotina LV1, Manziuk LV2, Gorbunova VA2, Kovalenko EI2, Mukhametshina GZ3, Khasanova AI3, Vladimirova LY.4, Mitashok IS4, Prokofyeva EP5, Evstigneeva IV6, Andreyashkina II7, Abramova NA4, Popova IL4, Karabina EV8, Teterich AA9, Gaysina EA10, Chubenko VA11, Limareva SV2, Tikhanovskaya NM4, Storozhakova AE4, Samaneva NY.4, Svetitskaya Y.V4, Snezhko TA4, Kalabanova EA4
-
Affiliations:
- P.A.Herzen Moscow Research Institute of Oncology of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
- N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- Tatarstan Regional Clinical Cancer Center
- Rostov Research Institute of Oncology
- SFHI Penza Regional Oncology Dispensary
- Tver Regional Clinical Oncology Dispensary
- Saratov Regional Oncology Dispensary No.2
- Tula Regional Oncology Dispensary
- Belgorod Regional Oncology Dispensary
- State Autonomous institution of public Health «Multidisciplinary Clinical Medical Center «Medical Town»
- SFHI St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic)
- Issue: Vol 18, No 3 (2016)
- Pages: 27-32
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27073
- ID: 27073
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
L V Bolotina
P.A.Herzen Moscow Research Institute of Oncology of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Email: lbolotina@yandex.ru
д-р мед. наук, зав. отд-нием химиотерапии ФГБУ МНИОИ им. П.А.Герцена ФГБУ НМИРЦ 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3
L V Manziuk
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием изучения новых противоопухолевых препаратов ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
V A Gorbunova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E I Kovalenko
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. отд-ния изучения новых противоопухолевых препаратов ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
G Z Mukhametshina
Tatarstan Regional Clinical Cancer Centerканд. мед. наук, зав. отд-нием химиотерапии №1 ГАУЗ РКОД 420029, Russian Federation, Kazan, ul. Sibirskii trakt, d. 29
A I Khasanova
Tatarstan Regional Clinical Cancer Centerканд. мед. наук, зав. дневным стационаром №1 ГАУЗ РКОД 420029, Russian Federation, Kazan, ul. Sibirskii trakt, d. 29
L Yu Vladimirova
Rostov Research Institute of Oncologyд-р мед. наук, проф., зав. отд-нием противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
I S Mitashok
Rostov Research Institute of Oncologyзав. отд-нием противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
E P Prokofyeva
SFHI Penza Regional Oncology Dispensaryзав. отд-нием химиотерапии дневного стационара ГБУЗ ООД 440002, Russian Federation, Penza, pr-t Stroiteley, d. 37A
I V Evstigneeva
Tver Regional Clinical Oncology Dispensaryзав. диспансерным отд-нием ГБУЗ ТО ТОКОД 170008, Russian Federation, Tver, ul. 15 let Oktiabria, d. 57/37
I I Andreyashkina
Saratov Regional Oncology Dispensary No.2канд. мед. наук, зав. отд-нием химиотерапии ГУЗ ООД №2 410053, Russian Federation, Saratov, Smirnovskoe ushhelye, d. 1
N A Abramova
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
I L Popova
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
E V Karabina
Tula Regional Oncology Dispensaryзав. химиотерапевтическим отд-нием ГУЗ ТООД 300040, Russian Federation, Tula, ul. Plehanova, d. 201a
A A Teterich
Belgorod Regional Oncology Dispensaryзав. дневным стационаром ОГБУЗ БОД 308010, Russian Federation, Belgorod, ul. Kuibysheva, d. 1
E A Gaysina
State Autonomous institution of public Health «Multidisciplinary Clinical Medical Center «Medical Town»зам. глав. врача по терапии ГАУЗ ТО МКМЦ Медицинский город 625041, Russian Federation, Tiumen, ul. Barnaul'skaia, d. 32
V A Chubenko
SFHI St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic)канд. мед. наук, зав. отд-нием химиотерапии ГБУЗ СПб КНпЦСВМП(о) 197758, Russian Federation, St. Petersburg, pos. Pesochnyj, Leningradskaja ul., d. 68A
S V Limareva
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N M Tikhanovskaya
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
A E Storozhakova
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
N Yu Samaneva
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
Ya V Svetitskaya
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
T A Snezhko
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
E A Kalabanova
Rostov Research Institute of Oncologyврач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63
References
- Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 28.07.2016).
- Towle M.J, Salvato K.A, Wels B.F et al. Eribulin induces irreversible mitotic blockade: implications of cell - based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71 (2): 496-505.
- Funahashi et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sciens 2014; 105 (10): 1334-42.
- Ueda S, Saeki T, Takeuchi H et al. In vivo imaging of eribulin - induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 2016.
- Partridge A.H et al. Chemo - and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer. J Clin Oncol 2014; 32: 3307-29.
- Advanced Breast Cancer Third International Consensus Conference; 5-7 November 2015: Lisbon, Portugal.
- Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open - label randomised study. Lancet 2011; 377 (9769): 914-23.
- Kaufman P.A, Cortes J, Awada A et al. Phase III open - label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol 2015; 33 (6): 594-601.
- Twelves C, Awada A, Cortes J et al. Subgroup Analyses from a Phase 3, Open - Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic Clin Res 2016: 10 77-84.
- Pivot X, Marmé F., Koenigsberg R et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27: 1525-31.
- Fornier M.N. Approved agents for metastatic breast cancer. Semin Oncol 2011; 38 (Suppl. 2): S3-S10.
- Cortes J, Vahdat L, Blum J.L et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28 (25): 3922-8.
- Van Persijn van Meerten E.L, Gelderblom H, Bloem J.L. RECIST revised: implications for the radiologist. A review article on the modi ed RECIST guideline. Eur Radiol 2010; 20 (6): 1456-67.
- Blum J.L, Twelves C.J, Dutcus C et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX. USA. P6-13-01.
- Twelves C et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open - label, phase 2 dose - confirmation study. Presented at SABCS 2014. Abstract. P3-13-04.
- Wilks S, Puhalla S, O'Shaughnessy J et al. Phase 2, multicenter, singlearm study of eribulin mesylate with trastuzumab as first Line therapy for locally recurrent or metastatic HER2positive breast cancer. Clin Breast Cancer 2014; 14: 405-12.